Keunchil Park

73.0k total citations · 12 hit papers
567 papers, 27.4k citations indexed

About

Keunchil Park is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Keunchil Park has authored 567 papers receiving a total of 27.4k indexed citations (citations by other indexed papers that have themselves been cited), including 398 papers in Pulmonary and Respiratory Medicine, 385 papers in Oncology and 95 papers in Molecular Biology. Recurrent topics in Keunchil Park's work include Lung Cancer Treatments and Mutations (342 papers), Lung Cancer Research Studies (160 papers) and Lung Cancer Diagnosis and Treatment (105 papers). Keunchil Park is often cited by papers focused on Lung Cancer Treatments and Mutations (342 papers), Lung Cancer Research Studies (160 papers) and Lung Cancer Diagnosis and Treatment (105 papers). Keunchil Park collaborates with scholars based in South Korea, United States and France. Keunchil Park's co-authors include Myung‐Ju Ahn, Jin Seok Ahn, Jong‐Mu Sun, Se‐Hoon Lee, Johan Vansteenkiste, Filippo de Marinis, Joachim von Pawel, Jeeyun Lee, U. Gatzemeier and Yoon‐La Choi and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Keunchil Park

558 papers receiving 26.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

2008 2.5k citations Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology profile →
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

2016 2.1k citations Johan Vansteenkiste, Keunchil Park et al. profile →
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

2009 1.0k citations Robert Pirker, Jose R. Pereira et al. profile →
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

2012 776 citations Keunchil Park, James Chih‐Hsin Yang et al. The Lancet Oncology profile →
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

2012 611 citations Keunchil Park, Dae Ho Lee et al. Journal of Clinical Oncology profile →
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

2011 453 citations Robert Pirker, Jose R. Pereira et al. The Lancet Oncology profile →
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

2018 336 citations Johan Vansteenkiste, Filippo de Marinis et al. The Lancet Oncology profile →
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

2015 331 citations Rodryg Ramlau, Keunchil Park et al. The Lancet Oncology profile →
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

2019 322 citations Jin Seok Ahn, Myung‐Ju Ahn et al. profile →
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

2021 165 citations Michael Boyer, Mehmet Alı Nahıt Şendur et al. Journal of Clinical Oncology profile →
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

2021 162 citations Ki Hyeong Lee, Keunchil Park et al. profile →
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Keunchil Park

Since Specialization

Citations

This map shows the geographic impact of Keunchil Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keunchil Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keunchil Park more than expected).

Fields of papers citing papers by Keunchil Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keunchil Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keunchil Park. The network helps show where Keunchil Park may publish in the future.

Co-authorship network of co-authors of Keunchil Park

This figure shows the co-authorship network connecting the top 25 collaborators of Keunchil Park. A scholar is included among the top collaborators of Keunchil Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keunchil Park. Keunchil Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study. 2024 ·Journal of Clinical Oncology ·M. Pérol, Kōichi Goto, Benjamin Solomon, Keunchil Park, Ernest Nadal, Emilio Bria, (unknown), Jair Bar, (unknown), Tarun Puri, Li J, (unknown), Boris K. Lin, Caicun Zhou	0
2	CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer 2024 ·Journal of Clinical Oncology ·M. Pérol, Benjamin Solomon, Kōichi Goto, Keunchil Park, Ernest Nadal, Emilio Bria, Claudio Martín, Jair Bar, (unknown), Tarun Puri, Li J, Minji K. Uh, Boris K. Lin, Caicun Zhou	5
3	Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023 ·Cancer Research and Treatment ·Hana Kim, Sehhoon Park, Hyun Ae Jung, Se‐Hoon Lee, Keunchil Park, Yong Chan Ahn, Dongryul Oh, Myung‐Ju Ahn	14
4	Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer 2023 ·Cancer ·Sehhoon Park, Yu Jung Kim, Young Joo Min, Peter G. Mortimer, Heejung Kim, Simon A. Smith, Emma Dean, Hyun Ae Jung, Jong‐Mu Sun, Woong‐Yang Park, Jin Seok Ahn, Myung‐Ju Ahn, Se‐Hoon Lee, Keunchil Park	15
5	Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial breakdown → 2022 ·Journal of Clinical Oncology ·Alexander Drilon, Vivek Subbiah, Oliver Gautschi, Pascale Tomasini, Filippo de Braud, Benjamin Solomon, Daniel S.W. Tan, Guzmán Alonso, Jürgen Wolf, Keunchil Park, Kōichi Goto, Victoria Soldatenkova, (unknown), Scott Barker, Tarun Puri, Aimee Bence Lin, Herbert H. Loong, Benjamin Besse	119
6	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib 2022 ·Clinical Lung Cancer ·D. Ross Camidge, Teresa Morán, Ingel Demedts, (unknown), Kathryn F. Mileham, Julian R. Molina, Óscar Juan, Gerold Bepler, Jonathan W. Goldman, Keunchil Park, Johan Wallin, Sameera R. Wijayawardana, Xuejing Aimee Wang, Volker Wacheck, Egbert F. Smit	19
7	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer 2021 ·Clinical Cancer Research ·Kazuhiko Nakagawa, Ernest Nadal, Edward B. Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin‐Yuan Shih, Luis Paz‐Ares, Bente Frimodt‐Moller, Annamaria H. Zimmermann, Sameera R. Wijayawardana, Carla Visseren‐Grul, Martin Reck, (unknown)	29
8	Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations 2021 ·Future Oncology ·Edward S. Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James Chih‐Hsin Yang	18
9	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study breakdown → 2021 ·Journal of Clinical Oncology ·Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, İrfan Çiçin, Perran Fulden Yumuk, Francesco Orlandi, Ticiana Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te‐Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck, (unknown)	165
10	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non–small Cell Lung Cancer 2020 ·Clinical Cancer Research ·Helena A. Yu, Luis Paz‐Ares, James Chih‐Hsin Yang, Ki Hyeong Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R. Wijayawardana, Ling Gao, Rebecca R. Hozak, Bo H. Chao, David Planchard	31
11	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery 2020 ·Journal of Korean Neurosurgical Society ·Min Ho Lee, Kyung Rae Cho, Jung Won Choi, Doo‐Sik Kong, Ho Jun Seol, Do‐Hyun Nam, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Jung-Il Lee	11
12	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors 2019 ·Clinical Cancer Research ·Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su‐Hyung Park, Keunchil Park, Myung‐Ju Ahn, Eui‐Cheol Shin	132
13	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC 2019 ·Journal of Thoracic Oncology ·Sehhoon Park, Hayoon Lee, Boram Lee, Se‐Hoon Lee, Jong‐Mu Sun, Woong‐Yang Park, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park	58
14	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib 2015 ·Clinical Cancer Research ·Ji Yun Lee, Jong‐Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa‐Na Song, Bo Mi Ku, Jiae Koh, (unknown), Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	28
15	The Effect of N/P Ratio on the In Vitro and In Vivo Interaction Properties of PEGylated Poly[2‐(dimethylamino)ethyl methacrylate]‐Based siRNA Complexes 2013 ·Macromolecular Bioscience ·(unknown), (unknown), Young-Wook Kim, Keunchil Park, You‐Yeon Won	66
16	The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor 2012 ·Molecular Cancer Therapeutics ·Young-Wook Kim, Jeong‐Hun Ko, (unknown), Amir Abolhoda, Jin Seok Ahn, (unknown), Myung‐Ju Ahn, Keunchil Park	144
17	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study breakdown → 2011 ·The Lancet Oncology ·Robert Pirker, Jose R. Pereira, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Keunchil Park, Filippo de Marinis, Wilfried Eberhardt, Luis Paz‐Ares, Stephan Störkel, (unknown), Anja von Heydebreck, Ilhan Celik, Kenneth J. O’Byrne	453
18	Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer breakdown → 2008 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, U. Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, (unknown), Anders Mellemgaard, Keunchil Park, (unknown), Janusz Rolski, Tuncay Göksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David R. Gandara	2487
19	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma 2007 ·Blood ·Sarah Park, Jeeyun Lee, Young Hyeh Ko, Arum Han, Hyun Jung Jun, Sang Chul Lee, In Gyu Hwang, Winnie Yeo, Jin Seok Ahn, Chul Won Jung, Kihyun Kım, Yong Chan Ahn, Won Ki Kang, Keunchil Park, Won Seog Kim	242
20	Interferon-α resistance can be reversed by inhibition of IFN-α-induced COX-2 expression potentially via STAT1 activation in A549 cells 2006 ·Oncology Reports ·Jeeyun Lee, (unknown), Young‐Hyuck Im, (unknown), Joon Park, Kihyun Kım, Won Il Kim, Jin Seok Ahn, (unknown), Young Min Park, Won Ki Kang, Keunchil Park	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact